FLT3+ Blasts (AML)
Use
This test is used for the detection of FLT3 on blasts, which is instrumental in the analysis and diagnosis of acute myeloid leukemia (AML). By including a comprehensive panel of markers such as icTdT, icMPO, CD64, CD10, CD19, icCD3, icCD79a, CD34, CD45, and FLT3, it provides essential information for clinical trials and research purposes. Due to its research-use nature, it supports the evaluation of FLT3 as a potential target in AML treatment strategies.
Special Instructions
The test is available for use strictly in clinical trials or research purposes, and it is not intended for primary clinical diagnosis. Turnaround times may vary based on specific biopharma protocol requirements and will be confirmed in the study contract.
Limitations
This assay is for research use only (RUO) and is not approved for clinical diagnostic purposes. The results are intended to assist researchers in understanding the role of FLT3 expression in AML and should not be used as a standalone diagnostic tool. Stability is limited to 48 hours post-collection, beyond which specimen integrity may be compromised.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
0.5 mL
Container
NaHep preferred (EDTA accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Specimens stored at incorrect temperature; Non-viable specimens; Specimens in inappropriate anticoagulant; Too few cells; Hemolysis; Specimen clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 48 hours |